6-[(2E)-2-{[5-(4-chloro-3-nitrophenyl)furan-2-yl]methylidene}hydrazinyl]-N-(4-fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazin-5-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-[(2E)-2-{[5-(4-chloro-3-nitrophenyl)furan-2-yl]methylidene}hydrazinyl]-N-(4-fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazin-5-amine
• 英文别名: 5-N-[(E)-[5-(4-chloro-3-nitrophenyl)furan-2-yl]methylideneamino]-6-N-(4-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine
• 化学式: C21H12ClFN8O4
• 分子量: 494.8
• InChiKey: JGNIZCBDGUWOEP-YSURURNPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  160
• 氢给体数：
  2
• 氢受体数：
  12

文献信息

• Heterocyclic compounds as pharmaceutically active compounds
  申请人：Aulinger-Fuchs Katharina

  公开号：US20050143382A1

  公开（公告）日：2005-06-30

  The present invention relates to furazanopyrazine derivatives of the general formula (I): wherein: R′ represents —NR 1 R 2 or —OR 9 R″ represents —NR 5 —NR 3 R 4 , —NR 5 —OR b , —O—NR 3 R 4 ; wherein R 1 to R 9 in formula (I) represent independently of each other a variety of different substituents comprising alkyl, aryl, aralkyl, alkylaryl, heteroaryl groups and monofunctional moieties.

  本发明涉及通式(I)的呋嗪并吡嗪衍生物，其中：R′代表—NR1R2或—OR9；R″代表—NR5—NR3R4，—NR5—ORb，—O—NR3R4；在公式(I)中，R1至R9独立地代表多种不同的取代基，包括烷基、芳基、芳基烷基、烷基芳基、杂环芳基基团和单官能团。
• [EN] ANTIDIABETIC AGENTS WHICH EXHIBIT ACTIVITY AGAINST PPAR<br/>[FR] AGENTS ANTIDIABETIQUES A ACTIVITE ANTI-PPAR
  申请人：RANBAXY LAB LTD

  公开号：WO2005056536A1

  公开（公告）日：2005-06-23

  The present invention relates to alkanoic acids and their derivatives which exhibit activity against PPARs, and hence can be used as antidiabetic compounds. Compounds disclosed herein can be used as peroxisome proliferation activated receptor (PPAR) activator. Such compounds can be used as therapeutic agents for the treatment of diseases and conditions mediated through any of the isoforms of PPAR, diabetes and diabetes-associated complications, and treatment of diseases and conditions in which insulin resistance is the central pathophysiological mechanism and diseases or conditions such as Type II diabetes, dyslipidaemia, hypertension, coronary heart disease, cardiovascular disease, atherosclerosis, nephrosclerosis, polycystic ovarian syndrome, eating disorders, diabetes nephropathy, glomerulonephritis, glomerularsclerosis, nephrotic syndrome, psoriasis or obesity. Processes for the preparation of the disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and methods for treating diabetes mellitus and the diseases and conditions mediated through insulin resistance are also provided.

  本发明涉及对PPARs具有活性的脂肪酸及其衍生物，因此可用作抗糖尿病化合物。本文所披露的化合物可用作过氧化物酶体增殖激活受体（PPAR）激活剂。这些化合物可用作治疗通过任何PPAR亚型介导的疾病和病症、糖尿病和糖尿病相关并发症、以及以胰岛素抵抗为中心病理机制的疾病和病症的治疗剂，如2型糖尿病、血脂异常、高血压、冠心病、心血管疾病、动脉硬化、肾硬化、多囊卵巢综合症、进食障碍、糖尿病肾病、肾小球肾炎、肾小球硬化、肾病综合征、牛皮癣或肥胖症等。本文还提供了制备所述化合物的方法、含有所述化合物的制药组合物以及治疗糖尿病和通过胰岛素抵抗介导的疾病和病症的方法。